Alnylam Pharmaceuticals Inc: (NASD: ALNY)
$27.99
0.42 (1.52%)
Volume 672,323
May 14 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 27.39 - 28.68 |
| 52wk Low - High | 9.51 - 28.68 |
| Previous Close | 27.57 |
| Avg. Volume | 446,781 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 1.71 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.27 |
| PE (Forward) | 0.00 |
| Current Year Est. | -1.30 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Outperform |
Zacks Industry Rank
|
79 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.30 |
| Current Quarter Estimate | -0.34 |
| Most Accurate Estimate | -0.34 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-05-2013 |
| EPS Last Year | -1.37 |
| Expected Earnings Growth | NA |
Company Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.34 | -0.36 | -1.30 | -1.77 |
| Number of Estimates | 4 | 4 | 5 | 4 |
| Low Estimate | -0.38 | -0.41 | -1.42 | -2.09 |
| High Estimate | -0.31 | -0.32 | -1.10 | NA |
| Year Ago EPS | -0.25 | -0.38 | -1.48 | -1.30 |
| EPS Growth | -34.00% | 4.61% | 12.43% | -36.38% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ALNYLAM PHARMA | ALNY | 27.57 | |
|
| AETERNA ZENTARS | AEZS | 1.87 | |
|
| ANIKA THERAPEUT | ANIK | 13.90 | |
|
| GENTIUM SPA-ADR | GENT | 8.31 | |
|
| NOVELOS THERAPT | NVLT | 0.44 | |
|
| AASTROM BIOSCI | ASTM | 0.60 | |
|
| ACHILLION PHARM | ACHN | 7.25 | |
|
| AFFYMAX INC | AFFY | 1.31 | |
|
| ALEXION PHARMA | ALXN | 104.86 | |
|
| ALKERMES INC | ALKS | 31.47 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Zacks #1 Rank Additions for Thursday
May 09, 2013
Alnylam Narrows Loss, Sales Fall
May 07, 2013
Pipeline Progresses at ViroPharma
Apr 23, 2013
FDA Approves Novartis' Simbrinza
Apr 22, 2013
Zacks Rank #1 Addition for Monday
Apr 22, 2013
Alnylam Initiates ALN-TTRsc Study
Mar 19, 2013
Loss Widens at Alnylam, Sales Fall
Feb 08, 2013
Alnylam-MDCO Join for ALN-PCS
Feb 05, 2013
Financials
| EPS TTM | -1.37 |
| Sales | 67 |
| Net Income | -104 |
| Price/Earnings | NA |
| Price/Book | 5.47 |
| Price/Cash Flow | NA |
| Price/Sales | 26.33 |
News
Alnylam Pharmaceuticals Looks to Continue to Trade Above its Annual-High Share Price Today - Financial News Netwfork Online - 52-Week High-Lows
May 13, 2013
Alnylam Pharmaceuticals Shares Climbing Higher, Up 5.2% - Financial News Network Online - Market Movers
May 13, 2013
Trading Higher on Heavy Volume are Shares of Alnylam Pharmaceuticals on 1.7x Above-Average Volume (ALNY) - Financial News Network Online - Unusual Volume
May 13, 2013
Very Narrowly Mixed on the Day - Advicetrade
May 13, 2013
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (ARNA, RGEN, ALNY, EXAS, ARIA) - Financial News Network Online - News Corner
May 10, 2013
Best Relative Performance in the Biotechnology Industry Detected in Shares of Arena Pharmaceuticals (ARNA, RGEN, ALNY, EXAS, ARIA) - Financial News Network Online - News Corner
May 9, 2013
Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference - Businesswire
May 8, 2013
Arena Pharmaceuticals has the Best Relative Performance in the Biotechnology Industry (ARNA, RGEN, ALNY, EXAS, ARIA) - Financial News Network Online - News Corner
May 8, 2013
Broker Recommendations
| Current ABR | 1.60 |
| ABR (Last Week) | 1.60 |
| # of recs in ABR | 5 |
| Average Target Price | 31.00 |
| Industry Rank by ABR | 79 out of 265 |
| Rank in Industry | 5 out of 155 |
